Abstract
Fas ligand (FasL) is involved in tumor evasion from the immune system. We analyzed 22 human gliomas for expression of FasL and its receptor, Fas. Positive FasL and Fas immunoreactivity was detected in 13 out of 22 tumors by Western blotting and in 15 out of 22 tumors by immunohistochemistry. Immunohistochemistry also showed that Fas and FasL expression was confined to tumor cells. Co-expression of these molecules was confirmed by Western blotting and immunohistochemistry in 4 of 7 glioma cell lines. Co-expression of FasL and Fas within tumor cells suggests that their contribution in vivo to the process of immune system evasion and tumor cell apoptosis is complex and probably involves additional factors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 30 July 1997 / Revised, accepted: 1 October 1997
Rights and permissions
About this article
Cite this article
Husain, N., Chiocca, E., Rainov, N. et al. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95, 287–290 (1998). https://doi.org/10.1007/s004010050799
Issue Date:
DOI: https://doi.org/10.1007/s004010050799